Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:UTHR's Cash to Debt is ranked higher than
95% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. NAS:UTHR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:UTHR' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 28.04 Max: 15951.56
Current: No Debt
0.69
15951.56
Equity to Asset 0.81
NAS:UTHR's Equity to Asset is ranked higher than
67% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:UTHR: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
NAS:UTHR' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.68 Max: 0.97
Current: 0.81
0.37
0.97
Interest Coverage 466.45
NAS:UTHR's Interest Coverage is ranked lower than
65% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:UTHR: 466.45 )
Ranked among companies with meaningful Interest Coverage only.
NAS:UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 466.45
Current: 466.45
2.02
466.45
F-Score: 7
Z-Score: 12.18
M-Score: -1.71
WACC vs ROIC
13.06%
97.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 65.38
NAS:UTHR's Operating margin (%) is ranked higher than
98% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. NAS:UTHR: 65.38 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:UTHR' s Operating margin (%) Range Over the Past 10 Years
Min: -29.15  Med: 27.54 Max: 65.38
Current: 65.38
-29.15
65.38
Net-margin (%) 44.40
NAS:UTHR's Net-margin (%) is ranked higher than
96% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:UTHR: 44.40 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:UTHR' s Net-margin (%) Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 46.33
Current: 44.4
-17.52
46.33
ROE (%) 42.08
NAS:UTHR's ROE (%) is ranked higher than
97% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. NAS:UTHR: 42.08 )
Ranked among companies with meaningful ROE (%) only.
NAS:UTHR' s ROE (%) Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.04
Current: 42.08
-11.59
46.04
ROA (%) 32.16
NAS:UTHR's ROA (%) is ranked higher than
98% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. NAS:UTHR: 32.16 )
Ranked among companies with meaningful ROA (%) only.
NAS:UTHR' s ROA (%) Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.16
Current: 32.16
-6.75
32.16
ROC (Joel Greenblatt) (%) 204.27
NAS:UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. NAS:UTHR: 204.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:UTHR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.1  Med: 67.4 Max: 215.39
Current: 204.27
-43.1
215.39
Revenue Growth (3Y)(%) 18.50
NAS:UTHR's Revenue Growth (3Y)(%) is ranked higher than
71% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:UTHR: 18.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:UTHR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 18.5  Med: 37.9 Max: 260.9
Current: 18.5
18.5
260.9
EBITDA Growth (3Y)(%) 32.40
NAS:UTHR's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:UTHR: 32.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:UTHR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: 15.9 Max: 128
Current: 32.4
-56.2
128
EPS Growth (3Y)(%) 30.60
NAS:UTHR's EPS Growth (3Y)(%) is ranked higher than
84% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NAS:UTHR: 30.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:UTHR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: 14.9 Max: 153.6
Current: 30.6
-50.7
153.6
» NAS:UTHR's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

UTHR Guru Trades in Q4 2015

Ray Dalio 28,161 sh (New)
Paul Tudor Jones 2,900 sh (New)
George Soros 4,400 sh (New)
Lee Ainslie 10,570 sh (+9.65%)
Joel Greenblatt 328,310 sh (+9.00%)
Ken Fisher 3,137 sh (+7.51%)
John Hussman Sold Out
First Eagle Investment Sold Out
Jim Simons 552,078 sh (-36.31%)
» More
Q1 2016

UTHR Guru Trades in Q1 2016

David Dreman 125 sh (New)
Ray Dalio 85,833 sh (+204.79%)
Lee Ainslie 20,930 sh (+98.01%)
Paul Tudor Jones 4,600 sh (+58.62%)
Joel Greenblatt 362,565 sh (+10.43%)
George Soros Sold Out
Ken Fisher 3,092 sh (-1.43%)
Jim Simons 474,578 sh (-14.04%)
» More
Q2 2016

UTHR Guru Trades in Q2 2016

David Dreman 2,670 sh (+2036.00%)
Lee Ainslie 26,710 sh (+27.62%)
Joel Greenblatt 367,075 sh (+1.24%)
Ken Fisher 3,092 sh (unchged)
Jim Simons 404,300 sh (-14.81%)
Paul Tudor Jones 3,700 sh (-19.57%)
Ray Dalio 64,100 sh (-25.32%)
» More
Q3 2016

UTHR Guru Trades in Q3 2016

Paul Tudor Jones 10,104 sh (+173.08%)
Ray Dalio 113,805 sh (+77.54%)
Ken Fisher 3,124 sh (+1.03%)
David Dreman 2,670 sh (unchged)
Lee Ainslie 25,910 sh (-3.00%)
Jim Simons 390,100 sh (-3.51%)
Joel Greenblatt 317,358 sh (-13.54%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:IONS, NAS:EXEL, NAS:JAZZ, NAS:ALNY, NAS:TECH, NAS:TSRO, NYSE:XON, NAS:RARE, NAS:ACAD, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF, NAS:GLPG, NAS:KITE, NAS:ALKS, NAS:JUNO, NAS:BLUE, NAS:LGND, NAS:PRTA, OTCPK:ABCZF » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered under the skin or in the vein for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor act to inhibit the degradation of cyclic guanosine monophosphate n cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products which include: Flolan, Ventavis, Ilomedin, Tracleer, Revatio, Letairis, Veletri, Adempas, Opsumit, generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 8.47
UTHR's P/E(ttm) is ranked higher than
86% of the 298 Companies
in the Global Biotechnology industry.

( Industry Median: 27.49 vs. UTHR: 8.47 )
Ranked among companies with meaningful P/E(ttm) only.
UTHR' s P/E(ttm) Range Over the Past 10 Years
Min: 4.95  Med: 23.36 Max: 171.34
Current: 8.47
4.95
171.34
Forward P/E 8.38
UTHR's Forward P/E is ranked higher than
80% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 19.92 vs. UTHR: 8.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.47
UTHR's PE(NRI) is ranked higher than
86% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 27.33 vs. UTHR: 8.47 )
Ranked among companies with meaningful PE(NRI) only.
UTHR' s PE(NRI) Range Over the Past 10 Years
Min: 4.95  Med: 23.18 Max: 171.34
Current: 8.47
4.95
171.34
Price/Owner Earnings (ttm) 13.24
UTHR's Price/Owner Earnings (ttm) is ranked higher than
72% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. UTHR: 13.24 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
UTHR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.08  Med: 34.57 Max: 570.89
Current: 13.24
5.08
570.89
P/B 2.92
UTHR's P/B is ranked higher than
56% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. UTHR: 2.92 )
Ranked among companies with meaningful P/B only.
UTHR' s P/B Range Over the Past 10 Years
Min: 2.01  Med: 4.04 Max: 10.39
Current: 2.92
2.01
10.39
P/S 3.80
UTHR's P/S is ranked higher than
78% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. UTHR: 3.80 )
Ranked among companies with meaningful P/S only.
UTHR' s P/S Range Over the Past 10 Years
Min: 2.88  Med: 5.94 Max: 15.99
Current: 3.8
2.88
15.99
PFCF 13.32
UTHR's PFCF is ranked higher than
69% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. UTHR: 13.32 )
Ranked among companies with meaningful PFCF only.
UTHR' s PFCF Range Over the Past 10 Years
Min: 9.78  Med: 20.33 Max: 618.25
Current: 13.32
9.78
618.25
POCF 11.79
UTHR's POCF is ranked higher than
70% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 20.45 vs. UTHR: 11.79 )
Ranked among companies with meaningful POCF only.
UTHR' s POCF Range Over the Past 10 Years
Min: 8.33  Med: 17.91 Max: 46.12
Current: 11.79
8.33
46.12
EV-to-EBIT 4.11
UTHR's EV-to-EBIT is ranked higher than
77% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 20.32 vs. UTHR: 4.11 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 14.4 Max: 120.9
Current: 4.11
-31.2
120.9
EV-to-EBITDA 4.03
UTHR's EV-to-EBITDA is ranked higher than
78% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 16.98 vs. UTHR: 4.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 13.35 Max: 102.2
Current: 4.03
-33.7
102.2
PEG 0.25
UTHR's PEG is ranked higher than
95% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.03 vs. UTHR: 0.25 )
Ranked among companies with meaningful PEG only.
UTHR' s PEG Range Over the Past 10 Years
Min: 0.15  Med: 0.44 Max: 2.43
Current: 0.25
0.15
2.43
Shiller P/E 26.08
UTHR's Shiller P/E is ranked higher than
72% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. UTHR: 26.08 )
Ranked among companies with meaningful Shiller P/E only.
UTHR' s Shiller P/E Range Over the Past 10 Years
Min: 22.59  Med: 49.91 Max: 679.13
Current: 26.08
22.59
679.13
Current Ratio 4.41
UTHR's Current Ratio is ranked higher than
52% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. UTHR: 4.41 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.42 Max: 64.22
Current: 4.41
0.96
64.22
Quick Ratio 4.11
UTHR's Quick Ratio is ranked higher than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. UTHR: 4.11 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 5.2 Max: 64.22
Current: 4.11
0.9
64.22
Days Inventory 452.11
UTHR's Days Inventory is ranked lower than
94% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 129.09 vs. UTHR: 452.11 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 452.11
Current: 452.11
118.32
452.11
Days Sales Outstanding 51.41
UTHR's Days Sales Outstanding is ranked higher than
61% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. UTHR: 51.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 51.41
Current: 51.41
36.71
51.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. UTHR: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -1.4 Max: 4.3
Current: 3
-9.9
4.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.96
UTHR's Price/Net Cash is ranked lower than
64% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. UTHR: 8.96 )
Ranked among companies with meaningful Price/Net Cash only.
UTHR' s Price/Net Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.1 Max: 160.03
Current: 8.96
1.51
160.03
Price/Net Current Asset Value 5.65
UTHR's Price/Net Current Asset Value is ranked lower than
52% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. UTHR: 5.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
UTHR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.46  Med: 10.55 Max: 5533
Current: 5.65
1.46
5533
Price/Tangible Book 2.99
UTHR's Price/Tangible Book is ranked higher than
64% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. UTHR: 2.99 )
Ranked among companies with meaningful Price/Tangible Book only.
UTHR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 3.79 Max: 18.16
Current: 2.99
1.16
18.16
Price/Projected FCF 0.93
UTHR's Price/Projected FCF is ranked higher than
88% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. UTHR: 0.93 )
Ranked among companies with meaningful Price/Projected FCF only.
UTHR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 3.8 Max: 232.67
Current: 0.93
0.83
232.67
Price/Median PS Value 0.64
UTHR's Price/Median PS Value is ranked higher than
72% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. UTHR: 0.64 )
Ranked among companies with meaningful Price/Median PS Value only.
UTHR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1.36 Max: 259.2
Current: 0.64
0.53
259.2
Price/Peter Lynch Fair Value 0.34
UTHR's Price/Peter Lynch Fair Value is ranked higher than
96% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. UTHR: 0.34 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
UTHR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.21  Med: 1.02 Max: 5.82
Current: 0.34
0.21
5.82
Price/Graham Number 1.06
UTHR's Price/Graham Number is ranked higher than
78% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. UTHR: 1.06 )
Ranked among companies with meaningful Price/Graham Number only.
UTHR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.77  Med: 2.49 Max: 6.18
Current: 1.06
0.77
6.18
Earnings Yield (Greenblatt) (%) 24.15
UTHR's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. UTHR: 24.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UTHR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 5.4 Max: 40.2
Current: 24.15
0.8
40.2
Forward Rate of Return (Yacktman) (%) 37.27
UTHR's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 15.87 vs. UTHR: 37.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
UTHR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.4  Med: 1.1 Max: 56.9
Current: 37.27
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,595
EPS (TTM) $ 14.87
Beta1.44
Short Percentage of Float23.23%
52-Week Range $97.52 - 164.04
Shares Outstanding (Mil)42.42

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,610 1,760 1,619 1,605
EPS ($) 13.61 15.28 16.54 14.04
EPS w/o NRI ($) 13.61 15.28 16.54 14.04
EPS Growth Rate
(3Y to 5Y Estimate)
0.49%
Dividends Per Share ($)
» More Articles for NAS:UTHR

Headlines

Articles On GuruFocus.com
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
Worst Performance YTD: MasterCard, Lazard Aug 03 2016 
5 Mid-Cap Stocks With Low Enterprise Multiples Aug 03 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
United Therapeutics Is a Value Investor's Biotech Dream Apr 28 2016 
Cummins and Deckers are Candidates for a January Bounce Nov 20 2015 
Estimated Revenue Up 5% Stock Screen Nov 18 2015 

More From Other Websites
Hedge Funds Are Selling Patterson Companies, Inc. (PDCO) Dec 02 2016
Pig organs to save lives by end of decade: United Therape... Dec 01 2016
Hedge Funds Are Buying WellCare Health Plans, Inc. (WCG) Dec 01 2016
United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US :... Nov 09 2016
Palo Alto Investors’s Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and... Nov 08 2016
Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns Nov 04 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation... Nov 01 2016
UNITED THERAPEUTICS CORP Financials Nov 01 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Oct 31 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation... Oct 31 2016
United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss Oct 28 2016
United Therapeutics upgraded by Ladenburg Thalmann Oct 28 2016
Edited Transcript of UTHR earnings conference call or presentation 27-Oct-16 1:00pm GMT Oct 27 2016
United Therapeutics upping the ante on R&D spending Oct 27 2016
United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today Oct 27 2016
Q3 2016 United Therapeutics Corp Earnings Release - Before Market Open Oct 27 2016
United Therapeutics beats 3Q profit forecasts Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)